Audio version narrated by an AI voice.
Need To Know
DVA’s medical travel rules are intended to avoid unnecessary expenditure, but changes to established arrangements can shift substantial upfront costs onto veterans. Finding a closer provider does not necessarily establish clinically equivalent treatment, continuing case management or a safe handover. The Senate inquiry needs to determine whether DVA verifies those safeguards and monitors what happens after travel assistance changes.
———
Approved treatment means little when a veteran cannot afford the journey to receive it.
⸻
For veterans receiving regular hospital-based treatment interstate, getting to the hospital can be as important as securing approval for the treatment itself.
A journey previously arranged and paid for by the Department of Veterans’ Affairs (DVA) may instead become the veteran’s responsibility, involving repeated flights, ground transport and sometimes accommodation. Reimbursement might follow, but it may cover only part of the expense, leaving the veteran to find the money upfront.
Australia’s distances make that a serious financial consideration for anyone requiring ongoing care. Some treatments demand attendance every few weeks, regardless of how far the veteran lives from the hospital.
A veteran could miss necessary treatment because of a travel decision, even though no clinician has determined that treatment should stop.
DVA generally calculates assistance using the Place Where Appropriate Treatment is Available (PWATA), meaning the closest approved provider capable of delivering appropriate care. When DVA considers treatment available nearer home, it may limit reimbursement for a longer journey or decline to arrange that transport. Responsibility for booking, paying upfront and meeting any shortfall can then shift to the veteran.
Treatment approval and travel assistance are separate decisions, but both must work for the veteran to receive care.
Consider a hypothetical veteran receiving regular, effective treatment at an interstate hospital. DVA decides appropriate care is available closer to home and stops arranging the established journey, although the proposed alternative has not been confirmed as clinically equivalent.
Unable to afford repeated self-funded journeys without adequate reimbursement, the veteran eventually stops attending. Treatment remains approved, and the clinical need has not disappeared.
DVA could spend less on both travel and appointments no longer attended without knowing whether the veteran received appropriate care elsewhere.
I’m not suggesting that DVA deliberately engineers this outcome or that it happens routinely. But the possibility exposes a weakness in judging decisions by expenditure alone, particularly when costs may shift to families, hospitals or other services.
My writing stays free. If you’d like to help keep it going, you can chip in here.
Taxpayers shouldn’t fund unnecessary journeys when suitable treatment is genuinely available nearby. DVA also has a responsibility to examine clinical safety, treatment effectiveness and the proper use of public money.
However, finding another hospital or practitioner offering a similar procedure is not necessarily finding clinically equivalent treatment. Established care may involve years of medical history, medication management, specialist monitoring, coordination between clinicians and continuing case management.
A closer provider must be capable of delivering the same necessary standard of care, accepting the veteran within an appropriate timeframe and safely assuming responsibility for the treatment program. Merely identifying a service on a map does not establish that those conditions are satisfied.
Veterans sometimes relocate on medical advice for one condition while requiring established treatment for another. Moving house can change the travel calculation without changing the clinical reasons for continuing with a particular treating team.
DVA’s June 2024 guidance already recognised provider availability, specialist referrals and reasonable continuity of care as reasons to travel further. Pre-arranged transport remains available for eligible veterans, so the question is how DVA applies its existing rules when established arrangements change.
Evidence submitted to the Senate Foreign Affairs, Defence and Trade References Committee makes this distinction important. Women Veterans Network Australia argues that effective treating relationships should not be displaced simply because another provider is geographically closer (submission 5, PDF page 4).
Australian Peacekeeper and Peacemaker Veterans’ Association calls for consultation with treating clinicians, consideration of interruption risks and a workable transition before established care changes (submission 13, PDF page 2). Its concerns also extend to costs potentially shifted beyond DVA.
Australian Orthotic Prosthetic Association explains why expertise, equipment and appointment capacity matter when determining whether orthotic and prosthetic care is actually available (submission 19, PDF page 6). Applying that principle to other specialist and hospital-based treatment is my assessment, not a committee finding.
None of those submissions establishes how frequently veterans lose previously arranged travel or subsequently stop treatment. Together, they identify the clinical evidence that should support decisions to replace established arrangements.
I’ve experienced the reverse approval problem myself. As I explained in my 3 July article about my 87th infusion nearly being delayed, DVA had approved my travel while prior financial approval for the continuing treatment remained undecided.
I’ve also made formal ministerial representations on behalf of affected veterans about medical travel and the risk to established treatment. I’ve received no response, not even the courtesy of an acknowledgement.
Those experiences don’t establish a national pattern, but they explain why I’m concerned about decisions that appear separate administratively while affecting the same patient’s care. Neither an approved journey without treatment funding nor approved treatment without an affordable journey guarantees access.
My view of Australia’s Repatriation obligation remains straightforward: “If you send them, and you bend them, you mend them!” Government should establish accepted service-related clinical needs, apply appropriate safeguards and budget responsibly to make necessary care accessible.
Before the Senate Foreign Affairs, Defence and Trade References Committee reports, senators should ask how many established journeys DVA has stopped arranging, what clinically equivalent alternatives were verified and who agreed to take over ongoing case management. They should also establish whether affected veterans could afford upfront costs and whether their treatment continued, transferred safely or stopped.
I’d require DVA to demonstrate clinically equivalent treatment, appropriate expertise, available appointments, continuing case management and a safe handover before reducing established travel assistance. Documented clinical, safety and substantiated integrity exceptions should remain, with clear reasons and review rights.
Reducing unnecessary travel while appropriate care continues is responsible administration. Reducing expenditure because a veteran can no longer reach clinically necessary treatment is not evidence that Australia’s Repatriation responsibility has been met.
Should DVA have to demonstrate that clinically equivalent treatment, continuing case management and a safe handover are genuinely available before reducing travel assistance for established care? I’d be interested in your view.


